News and Press Releases

Read Veristat news and press releases to learn about our CRO service growth, geographic expansion in Europe and Asia, biotechnology preferred partnerships and small CRO acquisitions.

Posts about

Clinical Operations/Monitoring

Veristat Launches Business Operations in Spain and Names Dr. Montserrat Barceló to Vice...

Leading the Organic and Acquisition Growth of Veristat Operations Throughout Europe

Veristat Named a Top Patient Recruitment Company by PharmaTech Outlook

Delivering A Patient-Centric Approach to Recruitment and Retention for Clinical Trials

SOUTHBOROUGH, MA – December 7, 2020 –Veristat, a...

Veristat Expands Pharmacovigilance and Safety Services with Acquisition of Certus PV

Delivering on Customer Demand for Pharmacovigilance from Clinical Trial Conduct to Post-Marketing Support

Veristat Announces Global Cell and Gene Therapy Center of Excellence

Accelerating cell and gene therapy opportunities for patients by advancing access to knowledge and leveraging experience for sponsors to...

Veristat Launches A Flexible Virtual Clinical Trial Solution

Veristat Enhances Patient-Centricity Offering by Delivering Clinical Trials Directly to Patients

SOUTHBOROUGH, MA – September 30, 2020 – ...

Veristat Helps Antibe Therapeutics Complete Their Phase IIB Study During COVID-19

In early 2019, Veristat helped Antibe Therapeutics, a biotech company with a drug platform of game-changing therapeutics in pain and...

Veristat Strengthens Its European Presence with the Acquisition of TCTC

Increasing Its Footprint and Expanding Therapeutic Expertise to Guide Sponsors Throughout the Clinical Development Lifecycle

Veristat Advances Game-Changing Pain and Inflammation Therapy

Veristat continues to support Antibe Therapeutics, a biotech company with a drug platform of game-changing therapeutics in pain and...

Veristat Supports Antibe Therapeutics for Pain and Inflammation Study

Upon receiving approval from Health Canada, Antibe Therapeutics selected Veristat to immediately begin work on part one of a Phase 2B...